Immunophenotypic classification of XXXX and @entity1072 --an experience in the south-western area of the Cape Province of South Africa.

@entity1 @entity981 @entity5 @entity1072 @entity6444 @entity11511
Adequate @entity5 material was obtained for phenotypic classification using a standard library of monoclonal antibodies from 81 previously untreated @entity1 with @entity981 ( @entity981 ), @entity6444 ( @entity6444 ), or @entity1072 ( @entity1072 ). Sixty-one individuals were adults and 20 were @entity1 of 14 yr or younger. Fifty-eight of the @entity1 (72%) had @entity981 and the remaining 23 (28%) had @entity6444 or @entity1072 . Considering only the @entity1 with @entity981 (n = 58) the median age was 19 yr (range 3-69 yr): 9% were black, 43% were coloured, 48% were white, and the distribution between adult (n = 38) and paediatric @entity1 (n = 20) was comparable. Complete remission rate in the adults was 58% and in the paediatric group 85%. For the total group (n = 58) median duration of survival was 59 weeks for common, 39 weeks for null, 63 weeks for @entity11511 , and 13 weeks for B- @entity981 subtypes. In both the common and the null groups overall and disease-free survival was superior in the @entity1 . In contrast, no difference was evident in the @entity11511 group, which was also notable for its high incidence in young coloured males. The 15 @entity1 with @entity6444 and eight with @entity1072 were adults and all the cells were phenotypically of B lineage: in view of the small numbers no comments are possible about ethnic differences. A multi-centre collaborative study is needed to define the epidemiology of @entity5 in South Africa, with emphasis on differences among ethnically distinct subpopulations.
